Introduction {#s0005}
============

Vaginal rejuvenation refers to procedures that primarily reduce the width of the vagina for reasons of function and well-being ([@bb0045]). The concept is more than a thousand years old and was first described by Trotula in 1050 AD in *Treatments for Women*, wherein she sutured vaginal lacerations postdelivery. Since then, fueled by increased technological innovation, surgical and nonsurgical treatments have been developed.

Global awareness and changing trends {#s0010}
====================================

Today, with increasing life expectancy and women living longer, \> 20 million women are affected by uterine prolapse, birthing injuries, and incontinence. Causes for conditions such as vaginal relaxation syndrome or vulvovaginal laxity include vaginal delivery, natural aging, and atrophy. Aside from functional consequences, these conditions also have an effect on women's sexuality and sense of well-being. Until recently, it was a taboo topic to discuss these topics, even with a women's health care provider. This fact is highlighted by a survey conducted by the International Urogynaecological Association in 2012, which showed that 84% of physicians believed that vaginal laxity was underreported, and 95% believed that laxity affected sexual function ([@bb0200]).

Moreover, 40% of women have psychological distress from female sexual dysfunction, but only 14% consult a physician about sex during their lifetime ([@bb0030]). Today, through public awareness programs, physician education, and media sources, the barriers of communication on issues with regard to female sexual dysfunction and incontinence have been broken. Information on these conditions and treatments options are more readily available, and, as a result, the demand for such interventions is growing.

Aside from surgery, the advent of nonsurgical methods and energy sources for these indications is receiving tremendous response and patient acceptance ([@bb0145]). The American Society of Plastic Surgeons reported a 30% increase in the rate of vaginal rejuvenation procedures between 2005 and 2006 ([@bb0165]), and an Indian study also showed growing trends in the demand of esthetic vaginal procedures from 3.9% in 2012 to 28.97% in 2015 ([@bb0075]).

Clarity {#s0015}
=======

Female cosmetic genital surgery (FCGS) refers to a subset of treatments that address the vaginal appearance, and the term vaginal rejuvenation has evolved into an umbrella term that covers procedures that enhance vaginal esthetics, sexuality, and functionality. Common procedures include surgical (e.g., vaginal tightening, labia minoraplasty, labia majoraplasty, clitoral hood reduction, clitoral unhooding, lipofilling, and hymen reconstruction) or nonsurgical (e.g., energy-based treatments, platelet-rich plasma \[PRP\], and fillers) interventions ([@bb0045]).

Results interpretation {#s0020}
======================

The clinical results of procedures for these indications have been assessed in terms of safety and efficacy in several peer-reviewed studies. Although objective, validated measurements and scales are still lacking, indices commonly referred to include the Female Sexual Functional Index (FSFI; [@bb0225]), Millheiser Vaginal Laxity Scale ([@bb0175]), Millheiser Sexual Satisfaction Scale ([@bb0070]), visual analogue scale ([@bb0170]), International Consultation on Incontinence Questionnaire ([@bb0035]), Satisfaction Scores (Likert scale; [@bb0260]), and Vaginal Health Index ([@bb0040]).

Surgical vaginoplasty {#s0025}
=====================

Surgical vaginoplasty involves surgical vaginal tightening and the correction of vaginal damage or deformity. The procedure may be done under local or regional anesthesia in an office-based surgical facility and involves a full-length tightening of the vagina (i.e., not just of the introitus) whereby dissection occurs all the way up to the levators and laterally to the ischial spines. A depth of 7 to 8 cm is recommended for full-length tightening. The vagina can be resized to the exact dimension the patient desires. This procedure usually also includes perineoplasty because this requires remodeling and strengthening of the perineum. Complication rates of surgical vaginoplasty range from 2% to 3.77% and include dyspareunia, lack of lubrication, constipation, wound infection, hemorrhage, suture breakdown (mostly in the perineum), buttock pain for weeks, and rectal mucosa perforation ([@bb0185]).

Various studies have addressed different aspects of surgical vaginal tightening. In a study of 53 women undergoing surgical colporrhaphy, where the vaginal diameter is decreased by two-thirds, 66% of women showed a great improvement in their sex lives, 24% a significant improvement, and 10% slight or no improvement. There were two cases of wound dehiscence ([@bb0185]). Goodman et al. conducted a large multicenter study of 258 women with FCGS, including 47 cases of vaginoplasty. The researchers concluded that surgical vaginoplasty/perineoplasty showed a high rate of enhancement of sexual functioning in both women and their partners ([@bb0135]).

Another study showed that the Female Sexual Function score was globally improved after colpoperineoplasty in 79 women ([@bb0005]). Dyspareunia and low lubrication were reported as side effects. A recent study of 39 patients undergoing surgical vaginal tightening showed improvements in FSFI from 19.5 to 27 ([@bb0075]). This study also showed that 81.6% of patients were very satisfied, 14.5% satisfied, and 3.9% not satisfied with the FCGS procedures.

Noninvasive modalities {#s0030}
======================

Noninvasive procedures for ameliorating symptoms of genitourinary syndrome of menopause (GSM) are increasingly emerging in the form of energy-based devices and injectable agents, such as fillers and PRP ([@bb0220]).

Energy-based devices for vaginal rejuvenation harness power from radiofrequency (RF) or laser sources, such as carbon dioxide (CO~2~; 10,600 nm; [Table 1](#t0005){ref-type="table"}) and erbium-YAG (2940 nm; [Table 2](#t0010){ref-type="table"}), to induce thermal-dependent matrix remodeling ([@bb0110], [@bb0115]). Energy-based devices stimulate type 1 collagen production in the extracellular matrix via the stimulation of fibroblasts. This process results in the contracture of elastin fibers, neovascularization, and improved vaginal lubrication. A study by Ostrzenski on CO~2~ laser treatment for vaginal rejuvenation included 10 patients who were treated with a continuous-mode CO~2~ laser with defocus, where vaporization was stopped at the endopelvic fascia. The study showed a great clinical improvement after only one treatment ([@bb0180]).Table 1Clinical studies using CO~2~ lasers for vaginal rejuvenationTable 1StudyResults[@bb0245]\
77 patients, menopausalSignificant improvement in FSFI scores (14.8--27.2)\
17 patients inactive; normal sex life[@bb0120]\
CO2 + PRP + PFESignificant reduction in sexual discomfort[@bb0090]\
386 patients, postmenopausalEffective in treating vaginal epithelium and dyspareunia due to atrophy[@bb0205]\
48 patients, postmenopausalConfirmed safety, efficacy, satisfaction in reducing VVA symptoms[@bb0215]\
50 patients (41--66 years)VHI score: 8.9--21.6 (\< 15 VVA)\
VAS: statistics improvement in dyspareunia\
52% satisfied at 11 months[^1]Table 2Clinical studies using Er:YAG lasers for vaginal rejuvenationTable 2StudyResults[@bb0010]Improved tightening[@bb0110], [@bb0115]\
45 patients (postmenopausal)Significant decrease in vaginal dryness and dyspareunia[@bb0280]Effective and safe to treat vaginal laxity

Recent RF studies showed an increase in the small nerve fiber density in the papillary dermis ([@bb0130]; [Table 3](#t0015){ref-type="table"}). Posttreatment biopsy tests have demonstrated neocollagenesis and neoelastogenesis in the submucosa after RF ([@bb0160]; [Figure](#f0005){ref-type="fig"}). The creation of new elastin, which is relatively unique to RF, may contribute to treating vaginal laxity ([@bb0265]). Several types of RF devices exist, and some have been developed with specific hand pieces for the vaginal canal ([@bb0240]). Transurethral monopolar RF has also been used to treat stress urinary incontinence (SUI). Nonablative RF was used to achieve tightening of the vaginal canal ([@bb0085], [@bb0240]).Table 3Clinical studies on the use of radiofrequency devices for vaginal rejuvenationTable 3DeviceStudyNo. of patientsResultsAdverse effectsTTCRF[@bb0160]\
GSM; prospective RCT20VHI, ICIQ-UI, UDI6, IIQ7, VAS, punch biopsies\
Marked improvementNone[@bb0020]\
Prospective for laxity, UI23Statistically significant: Vaginal laxity, sexual satisfaction.\
Improved SUI, atrophy, orgasmsNone[@bb0025]\
Prospective for orgasms25Average reduced time to orgasm 50%\
Improved tightening, moisture, sensitivity\
Co-relates with histopathologyNoneCMRF[@bb0175]\
Prospective for laxity2487% improved in 6 months\
Sexual scores: 27.6--32\
Sustained improvement on SSQ at 6 monthsNone[@bb0250]\
Prospective for laxity30Significant FSFI: 22.4--26None[@bb0150]\
Randomized, placebo sham controlled multicenter study174Significant change in laxity 43.5% active gp v/s 19.6%NoneBIPOLAR RFWomen in 50s1464% satisfied with resultsNoneMONOPOLAR RF[@bb0050]\
Prospective for aesthetic appearance19Improvement in vulvar appearance and sexual functionNone[@bb0155]\
Mild/moderate SUI & vaginal laxity27Improvement in all evaluated areas of SUI and vaginal laxityNone[^2]FigVaginal mucosa (A) before and (B) 6 months after one treatment with the radiofrequency device ThermiVA (Thermiaesthetics, Irving, TX)Fig

Additional clinical effects of energy-based devices include the increase of glycogen content, as documented by histopathology ([@bb0265]). Energy-based vaginal rejuvenation procedures are appealing because they are noninvasive lunchtime procedures, with an average treatment time of 8 to 30 minutes depending on the indications and the method used ([Table 4](#t0020){ref-type="table"}). The procedure is usually painless, and no anesthesia is required. Two or three sittings are advocated, spaced approximately 1 month apart. A touch-up sitting or repeat single session is done after 12 to 18 months.Table 4Comparison of energy-based devicesTable 4RF devicesLasersMonopolarBipolar and other RFsCO~2~Erb:YAGSize and portabilityPortableUsually nonportableLarge and nonportableLarge and nonportableHand piecesDisposable, small ergonomic wandBarrel-shaped hand pieces for vagina, or small introital hand piecesLarger, barrel-shaped hand pieces with disposable sleeves that are attached to an articular armLarger, barrel-shaped hand pieces with disposable sleeves that are attached to an articular armDepth of penetration4 mm0.5 mm0.6 mm0.2--0.5 mmProcedure roomOutpatient roomDesignated procedure roomSpecial room with laser-specific regulation requiredSpecial room with laser-specific regulation requiredSafetyNo special safety gear requiredNo special safety gear requiredUser-laser protection glasses, etcUser-laser protection glasses, etcFrequency of sittings3--4 sittings at monthly intervals4--6 sittings at 2--3 week intervals (bipolar), 3 sittings, each a week apart (multipolar), single Rx (patented), 2--4 times every 2--4 weeks (focused)3--4 sittings @ 4--6 week intervalsProtocols are different for different machines:\
2 Rx at 8 weeks (Intimalaser) 3 Rx at 2 weeks (Petit Lady)AnesthesiaNo anesthesiaNoNoNoTime taken15--30 minutes10--20 minutes8--20 minutes8--20 minutesDowntimeNoneNoneSexual intimacy after 3 daysSexual intimacy after 3 daysPainNo painIntroital area may be painful with pre-heated ringsPain near introitus; hence, need to decrease energy in that areaPain near introitus; hence, need to decrease energy in that areaEffects last for12 months12 months12 months12 monthsFunctional probeSame probe can be used on vulva, in anal canal, or on the penile shaftSeparate probes for vagina and vulvaSeparate probe used on vulvaSeparate probe used on vulvaSkin lightening―Separate probe for skin lighteningSeparate probe for skin lighteningUpgrade the machinesNewer machines with higher voltage; hence, quicker action―Automated laser dispensers (robotic) arms make the procedure user independent and faster. Some machines are now adding an RF probe to work on the introital areaRobotic arms make the procedure user independent and faster. Some machines are now adding an RF probe to work on the introital area[^3]

Energy-based procedures are well tolerated by most patients because they are either totally pain-free or cause slight discomfort. There is no downtime, and usual daily activities can be immediately resumed (except for sexual activity in laser treatments, after which 3 days of abstinence is recommended). Patients who benefit the most from energy-based procedures are those who have symptoms of mild-to-moderate SUI, overactive bladder, vaginal dryness, decreased lubrication, orgasmic dysfunction, grade 1 prolapse, and vaginal laxity. The indications are ever increasing, but more studies are required to evaluate the true breadth of the efficacy of energy-based devices.

In 2013, the North American Menopause Society validated energy-based devices; the society passed a position statement acknowledging that the use of lasers appeared to be an emerging therapy and may provide clinicians with other options to treat common and distressing problems of GSM ([@bb0025]; [@bb0125], [@bb0160], [@bb0265]).

Other noninvasive modalities for vaginal rejuvenation involve the use of injectable volumizers, such as hyaluronic acid, PRP, and physical devices (e.g., Gore-Mycromesh and silicone threads). Aside from addressing laxity in the canal and dryness, some of these techniques specifically enhance the female sexuality center (e.g., amplify the G-spot).

Lipo-filling {#s0035}
------------

A minimally invasive technique of vulvovaginal lipo-filling of the posterior vaginal wall was performed by Aguilar et al. in 2016. They also injected hyaluronic acid and PRP subcutaneously in the perineum ([@bb0015]).

Gore-mycromesh {#s0040}
--------------

In 2015, Park et al. did a study using a biocompatible compound (expanded poly-tetrafluoroethylene) as a Gore-Mycromesh on 50 women. They inserted, under local anesthesia, a 2 × 4 cm^2^ mesh under the posterior wall submucosa. The results showed a substantial improvement in sexual function in a year, especially for FSFI rates of satisfaction ([@bb0190]).

Silicone threads {#s0045}
----------------

Park et al. performed a study among 180 women by inserting silicone threads under the vaginal submucosa ([@bb0195]). They made incisions at the 3 and 9 o'clock positions and found that the FSFI significantly improved, especially for orgasms. Of their patients, 92.8% were satisfied with the vaginal width correction. Complications included implant exposure (5%), capsule contracture (3.9%), and infection (1.7%).

G-spot amplification {#s0050}
--------------------

This procedure, which was empirically developed, makes the G spot more prominent and, hence, increases friction, which leads to better chances of vaginal orgasm. Bulking the sensitive area forward toward the vaginal lumen for greater frictional contact may lead to easier, longer, more frequent and intense orgasms. The G-spot was first described by Gräfenberg ([@bb0140]) and named by Perry and Whipple ([@bb0210]). It is located below or inferior to the urethra, midway between the pubic bone and cervix, and is believed to be responsible for vaginal-mediated orgasms. Methods of amplification include nonpermanent fillers (e.g., hyaluronic acid) as patented by Dr. David Matlock (called the G-shot), PRP, and collagen injections. The results of the G-shot may last 3 to 5 months, but the procedure is limited by a lack of randomized controlled data.

Combination treatments {#s0055}
======================

Combination treatments have increasingly been adopted for the comprehensive care of patients with esthetic and medical concerns. For vaginal rejuvenation, commonly proposed combination treatments include energy-based devices with PRP, energy-based devices after surgery, energy-based devices and fillers, and a combination of energy-based devices.

Energy-based devices with platelet-rich plasma {#s0060}
----------------------------------------------

PRP is the most common rejuvenating injectable used in various parts of the body. Patients' venous blood is collected in special tubes and centrifuged to obtain a supernatant of PRP. PRP acts by being very rich in and promoting growth factors with a fibrin scaffolding. PRP has been combined with energy-based devices as follows: 1) PRP is applied after microablative lasers as a rejuvenating liquid in the vagina; and 2) PRP is injected in the clitoro-urethro-vaginal space for better orgasms and better urinary control for stress urinary incontinence after use of energy-based devices (e.g., the O Shot, as patented by Runnels \[[@bb0235]\]).

Energy-based devices after surgery {#s0065}
----------------------------------

With surgical vaginal tightening, the tissues are cut and resutured in layers with support that leads to structural and physical tightening. However, because energy-based devices improve the functionality of tissues, they can be offered to patients after a surgical vaginoplasty to improve elasticity and vaginal mucosa. Energy-based devices help improve symptoms of dyspareunia and lack of lubrication that are noted after surgery.

Energy-based devices and fillers {#s0070}
--------------------------------

G-spot amplification can be done in combination with the third treatment of energy-based devices for vaginal orgasms.

Combination of energy-based devices {#s0075}
-----------------------------------

Some clinicians combine a laser device with RF and use laser in the vaginal canal and RF for the introital area and the vulva. This has prompted certain laser companies to add a separate RF device for use on the introital area.

Position of leading medical bodies {#s0080}
==================================

There is no federal or state legislation that currently prohibits or limits FCGS in the United States ([@bb0055]). Despite the excitement of the medical and patient community about procedures to improve vaginal conditions and appearance and/or sexual health, several organizations have expressed concerns about the efficacy and safety of these procedures. Coupled with the paucity of peer-reviewed clinical trials, health care providers must tread the waters lightly so as not to run into medicolegal issues. We outlined the positions of the leading medical bodies.

American College of Obstetricians and Gynecologists {#s0085}
---------------------------------------------------

The American College of Obstetricians and Gynecologists Committee Opinion (2007, reaffirmed in 2017), indicated that FCGS is not medically indicated, and the safety and effectiveness of such procedures have not been documented. Women who ask for such procedures should be informed about the lack of data supporting their efficacy and about their potential complications, including infections, altered sensations, dyspareunia, scarring, and adhesions ([@bb0060]).

Royal College of Obstetricians and Gynecologists {#s0090}
------------------------------------------------

The Royal College of Obstetricians and Gynecologists stated in 2013 that "Presenting FCGS procedures as an unproblematic lifestyle choice is inappropriate" ([@bb0230]).

Royal Australian and New Zealand College of Obstetricians and Gynecologists, and Society of Obstetricians and Gynecologists of Canada {#s0095}
-------------------------------------------------------------------------------------------------------------------------------------

The Royal Australian and New Zealand College of Obstetricians and Gynaecologists Society of Obstetricians and Gynaecologists of Canada holds a public stand against FCGS ([@bb0270], [@bb0255]).

U.S. Food and Drug Administration {#s0100}
=================================

The U.S. Food and Drug Administration recently issued a stern warning ([@bb0275]) about procedures that destroy or reshape vaginal tissue using lasers or other energy-based devices, such as RF. The warning elaborates that \"the full extent of the risks is unknown. But these reports indicate these procedures can cause serious harm.\" The U.S. Food and Drug Administration warning does not include sufficient data to address safety or efficacy, but it underscores the need for more thorough and long-term studies to be conducted.

Ongoing clinical trials {#s0105}
=======================

Large, blinded, randomized control trials are required to establish appropriate indications, effects, and complications for energy-based devices. Several ongoing multicenter trials use fractional CO~2~ lasers in GSM, often comparing their efficacy with that of a topical estrogen preparation ([@bb0065]). The Vaginal Erbium Laser Academy Study for GSM and SUI is an international, multicenter trial, and the ThermiVa in Genital Hiatus Treatment trial is a multicenter Australian trial that investigates whether transcutaneous, temperature-controlled RF is an effective treatment for vaginal laxity ([@bb0080]).

Conclusions {#s0110}
===========

Energy-based devices undoubtedly show great promise for the functional and esthetic issues of women's intimate areas, especially vaginal rejuvenation. Larger, double-blinded, randomized control trials are required to draw definitive conclusions, including accepting these devices as standard, preventive, or first-line treatments.

Appendix A. Supplementary data {#s9050}
==============================
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[^1]: CO~2~, carbon dioxide; FSFI, Female Sexual Functional Index; VAS, visual analog scale; VHI, vaginal health index; VVA, vulvovaginal atrophy

[^2]: CMRF, cryogen-cooled monopolar radiofrequency; FSFI, Female Sexual Function Index; GSM, genitourinary symptoms of menopause; ICIQ, International Consultation on Incontinence Questionnaire; RCT, randomized control trial; RF, radiofrequency; SSQ, Sexual Satisfaction Questionnaire; SUI, stress urinary incontinence; TTCRF, transcutaneous temperature controlled radiofrequency; UI, urinary incontinence; VAS, visual analogue scale; VHI, vaginal health index

[^3]: CO~2~, carbon dioxide; RF, radiofrequency; Rx, prescription
